Viewing Study NCT06590558

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:16 AM
Ignite Modification Date: 2026-03-01 @ 1:26 PM
Study NCT ID: NCT06590558
Status: WITHDRAWN
Last Update Posted: 2025-07-03
First Post: 2024-09-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anatomic Stage III Breast Cancer AJCC v8 View
None Anatomic Stage IV Breast Cancer AJCC v8 View
None Invasive Breast Carcinoma View
None Locally Advanced HER2-Negative Breast Carcinoma View
None Locally Advanced Hormone Receptor-Positive Breast Carcinoma View
None Locally Advanced Triple-Negative Breast Carcinoma View
None Metastatic HER2-Negative Breast Carcinoma View
None Metastatic Hormone Receptor-Positive Breast Carcinoma View
None Metastatic Triple-Negative Breast Carcinoma View
None Unresectable HER2-Negative Breast Carcinoma View
None Unresectable Hormone Receptor-Positive Breast Carcinoma View
None Unresectable Triple-Negative Breast Carcinoma View
Keywords: